Navigation Links
Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
Date:5/27/2009

/p>

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulatio
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009
4. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
5. Spectros T-Stat Tissue Oximeter Clinical Studies Presented at PAS (Pediatric Academic Societies) Conference
6. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
7. goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites
8. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
9. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
10. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... WARREN, N.J. , May 5, 2015 Roka ... focused on providing advanced testing solutions for the detection of ... will present at the Bank of America Merrill Lynch 2015 ... conference will be held at Encore at the Wynn, ... live webcast of the presentation will be available through the ...
(Date:5/5/2015)... Hayden-McNeil is pleased to announce ... materials for smaller courses. This program is specifically designed ... students. , “I’m very excited about offering our ... instructors,” said Jeff McCarthy, Hayden-McNeil president. “By working with ... part to make education both more effective and affordable.” ...
(Date:5/5/2015)... TEL AVIV, Israel , May 5, 2015 ... that the Company was approved to continue trading ... companies. OTCQB Marketplace allows for ... an electronic broker-dealers. Investors can have real-time quotes ... The OTCQB Marketplace includes ...
(Date:5/5/2015)... Reprints Desk, Inc., a Research Solutions (OTCQB: ... scientific, technical and medical (STM) content, today announced a ... Southeastern Research Libraries (ASERL) . ASERL is ... southeastern states. Founded in 1956, ASERL has a long ... the continually changing needs of its member libraries. ...
Breaking Biology Technology:Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4
... LAVAL, QC, Oct. 15 /PRNewswire-FirstCall/ - Neptune ... is pleased to,announce the appointment of a ... comprised of 5 renowned scientists. Neptune ... of the new,members of the Advisory Board ...
... Oct. 15 Wyeth,Pharmaceuticals, a division of Wyeth ... presented today at the 63rd Annual Meeting of ... women who received 100 mg/day or,150 mg/day of ... a significant reduction in moderate to severe,vasomotor symptoms ...
... Inc.,(Nasdaq: ORCH ), a leading worldwide provider ... quarter 2007 financial results on,Thursday, November 1, 2007 ... a,conference call and webcast to discuss the results ... will discuss financial results for the third quarter,2007 ...
Cached Biology Technology:Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board 2Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board 3Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 2Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 3Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 4Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 5Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1, 2007 2
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... of Pennsylvania survey of dog owners who use confrontational ... have found that most of these animals will continue ... The study, published in the current issue of ... non-aversive or neutral training methods such as additional exercise ...
... Singapore Centre for Drug Discovery (LSCDD), Singapore,s National Neuroscience ... (SICS), have teamed up to advance drug discovery using ... one of the institutions of SingHealth, the largest public ... of the US-based biopharmaceutical company, Eli Lilly and Company ...
... microscopic channels called plasmodesmata that are embedded in their ... growing tips, called "meristems," the plasmodesmata are lifelines, allowing ... Developmental and environmental cues trigger changes in the ... of traffic through them. The genes and molecular pathways ...
Cached Biology News:If you're aggressive, your dog will be too, says veterinary study at University of Pennsylvania 2Singapore research organisations team up to advance drug discovery using brain tumor stem cells 2CSHL researchers identify gene that helps plant cells keep communication channels open 2CSHL researchers identify gene that helps plant cells keep communication channels open 3
Fujifilm BAS-1800II provides the ideal configuration for a low-cost imager that requires only a small amount of space in the laboratory. The small imager for accurate high-throughput screening...
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
... 384 is a compact and self-contained ... is a unique flow-through device, which ... included wash system. Optional refill ... system. Will be upgradable to ...
... The Eclipse C1 Plus is a ... highest-quality digital imaging with an ultra-compact and ... of the C1 Plusboost optical performance to ... acquisition.The system alsoincludes support for X and ...
Biology Products: